Project I covers the pathology activities essential to the conduct of the Trial. Quality assurance is provided by expert review of all primary tumors from patients entering the Trial, all sentinel/non-sentinel node material from Learning Phase cases and 20% of sentinel modes from Trial Phase cases. To assure uniformity of pathology in the Trial a videotape is provided to all pathologists involved, and annual meetings are held. Dr. Cochran provides help-line support and specific consultation as required. We proposed a detailed study of the amount of distribution of micrometastic and occult melanoma in regional nodes against survival. We will assess whether the sentinel node tumor burden can predict the need for completion lymphadenectomy. We will investigate the frequency and extent of immune modulation of sentinel nodes and relate this to outcome and extent of tumor penetration of the regional nodes. We will undertake a major study to determine whether our present sampling is sufficient. We will assess whether molecular biological techniques improve the accuracy of nodal evaluation over immunohistochemistry. We will continue to develop techniques to allow microscopic confirmation a node is sentinel. We will evaluate the accuracy of our newly developed prognostic models to determine their accuracy on an individual patient basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA029605-17
Application #
6269123
Study Section
Project Start
1998-09-10
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
17
Fiscal Year
1998
Total Cost
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Ozao-Choy, Junko; Nelson, Daniel W; Hiles, Jason et al. (2017) The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol 116:337-343
Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959
Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158
Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222
Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013
Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-541
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46
Marzese, Diego M; Huang, Sharon K; Hoon, Dave S B (2015) In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues. Methods Mol Biol :

Showing the most recent 10 out of 256 publications